---

Drugs for Liver Failure & Biliary Management - Katzung (16th Ed.)

1. HEPATIC CIRRHOSIS - Diuretics

Drugs and Their Use

• Overly aggressive diuresis causes intravascular volume depletion, hypokalemia, metabolic alkalosis
• Can precipitate hepatorenal syndrome and hepatic encephalopathy
• Aldosterone antagonists risk serious hyperkalemia in patients with even mild renal insufficiency

---

2. BILE ACID AGENTS (Biliary Management)

A. Ursodiol (Ursodeoxycholic acid)

• Pharmacokinetics: Orally absorbed; conjugated in liver with glycine or taurine; excreted in bile; undergoes extensive enterohepatic recirculation; t1/2 ~100 hours; with chronic use constitutes 30-50% of the bile acid pool.
• Mechanism:
  • Reduces hepatic cholesterol secretion → reduces cholesterol content of bile
  • Stabilizes hepatocyte canalicular membranes
  • Reduces concentrations of toxic endogenous bile acids
  • Has anti-inflammatory effects
• Clinical uses:
  1. Dissolution of small cholesterol gallstones in poor surgical candidates (dose: 10 mg/kg/d; takes 6-12 months)
  2. First-line treatment of primary biliary cirrhosis (PBC) (dose: 13-15 mg/kg/d) - improves liver biochemistry, slows histologic progression, reduces need for transplantation, improves survival. ~35% of patients do not respond.
• Adverse effects: Practically free of serious effects. Bile salt-induced diarrhea uncommon. No hepatotoxicity (unlike its predecessor chenodeoxycholic acid).

B. Obeticholic Acid (Ocaliva)

• Type: Synthetic derivative of chenodeoxycholic acid
• Mechanism:
  • Nontoxic bile acid that decreases hepatic concentrations of toxic endogenous bile acids
  • Ligand for the farnesoid X receptor (FXR) - modulates hepatic inflammation, fibrosis, gluconeogenesis, lipid synthesis, and insulin sensitivity
• Clinical uses:
  1. PBC: 5-10 mg/d orally, in combination with ursodiol, in patients with inadequate ursodiol response. ~50% clinical response vs. 10% with ursodiol alone in trials.
  2. Being evaluated for non-alcoholic steatohepatitis (NASH) - 25 mg/d for 18 months showed significant improvement in fibrosis (not yet FDA-approved for NASH).
• Adverse effects: Severe pruritus in up to 25% of patients (especially at 10 mg dose); leads to discontinuation in ~10%.

---

3. DRUGS USED TO TREAT VARICEAL HEMORRHAGE

A. Somatostatin & Octreotide

• Mechanism: Reduce portal blood flow and variceal pressures, likely via inhibition of glucagon and other gut peptides that regulate mesenteric blood flow (not direct vascular smooth muscle contraction)
• Use: Active variceal hemorrhage - administered for 3-5 days
• Dosing: Somatostatin 250 mcg/h IV; Octreotide 50 mcg/h IV

B. Vasopressin & Terlipressin

• Vasopressin: Potent arterial vasoconstrictor → splanchnic arterial vasoconstriction → reduced portal venous pressures. Largely replaced by octreotide due to serious adverse effects (hypertension, MI, mesenteric infarction, hyponatremia). May be combined with nitroglycerin to reduce coronary/peripheral vasospasm and further lower portal pressure.
• Terlipressin: Vasopressin analog; similar efficacy, fewer adverse effects; available in other countries but not FDA-approved in the USA.

C. Non-selective Beta-blockers (Propranolol, Nadolol)

• Mechanism: Reduce portal inflow via:
  • Beta-1 blockade → reduced cardiac output
  • Beta-2 blockade → splanchnic vasoconstriction (unopposed alpha effect on catecholamines)
• Uses:
  • Primary prophylaxis: In cirrhosis with esophageal varices, reduces bleeding incidence from 25% to 15%
  • Secondary prophylaxis: Reduces recurrent hemorrhage (recurrence otherwise ~80% within 2 years)
• Note: Selective beta-1 blockers are less effective than nonselective agents for this indication.

---

OTHER DRUGS IN THESE CLASSES (Beyond Katzung's Highlighted Agents)

Bile Acid / FXR-related Agents

Vasopressin Analogs (Variceal Hemorrhage/Portal Hypertension)

Aldosterone Antagonists (Diuretics in Liver Disease)

Vaptans (V2 Receptor Antagonists) - Hyponatremia in Cirrhosis

Somatostatin Analogs (for Portal Hypertension)

---

• In hepatic cirrhosis-associated ascites, spironolactone is preferred over loop diuretics due to the heightened aldosterone state. Loop diuretics are used as add-ons.
• Ursodiol is the cornerstone of PBC management; obeticholic acid is added when ursodiol fails.
• For acute variceal hemorrhage, octreotide has largely replaced vasopressin; non-selective beta-blockers are used for primary and secondary prophylaxis of variceal bleeding.
• Vaptans must be used carefully in liver disease - avoid in active hepatitis, may be useful in burned-out cirrhosis with hyponatremia.

---

Drugs for Liver Failure & Biliary Management - Full Detail (Katzung 16e)

---

PART 1 - HEPATIC CIRRHOSIS: ASCITES & EDEMA MANAGEMENT

Pathophysiology (Why These Drugs Are Used)

1. Elevated portal hydrostatic pressure - due to sinusoidal fibrosis and portal hypertension
2. Reduced plasma oncotic pressure - hypoalbuminemia from failed hepatic synthesis
3. Renal sodium retention - from:
   • Diminished renal perfusion (systemic vascular alterations)
   • Diminished plasma volume (ascites draws fluid)
   • Primary aldosterone excess (hyperaldosteronism) due to reduced hepatic aldosterone metabolism

---

A. Aldosterone Receptor Antagonists (FIRST-LINE)

Spironolactone

• Class: Non-selective mineralocorticoid receptor (MR) antagonist
• Mechanism: Competitively blocks aldosterone at the distal tubule and collecting duct → decreases sodium reabsorption → natriuresis without potassium loss
• Why it works best in cirrhosis: Cirrhotic edema is unusually responsive to spironolactone because the underlying pathology involves hyperaldosteronism
• Dose: Typically 100-400 mg/day; titrated to response
• Adverse effects:
  • Hyperkalemia (especially dangerous in patients with even mild renal insufficiency - use with considerable caution)
  • Gynecomastia, menstrual irregularities (due to anti-androgenic activity - it also blocks androgen receptors)
  • Impotence
• Other drugs in this class (MR antagonists):

---

Loop Diuretics (SECOND-LINE - Adjunct)

Furosemide

• Class: Loop diuretic; Na+/K+/2Cl- cotransporter inhibitor (thick ascending limb of Henle)
• Mechanism: Blocks NKCC2 → massive natriuresis
• Why it is less effective in cirrhosis:
  1. Decreased drug secretion into tubular fluid (hypoalbuminemia reduces protein-bound drug delivery)
  2. High circulating aldosterone levels counteract the diuresis
• Role: Used in combination with spironolactone when aldosterone antagonists alone are insufficient. The typical ratio used clinically is spironolactone:furosemide = 100 mg:40 mg
• Critical Katzung warning: Overly aggressive diuresis in cirrhosis causes:
  • Marked intravascular volume depletion
  • Hypokalemia and metabolic alkalosis
  • Hepatorenal syndrome (acute kidney injury)
  • Hepatic encephalopathy (precipitated by volume depletion and electrolyte shifts)
• Other loop diuretics:

---

B. Vaptans - Vasopressin V2-Receptor Antagonists (FOR HYPONATREMIA)

Tolvaptan

• Class: Selective vasopressin V2 receptor antagonist (aquaretic)
• Mechanism: Blocks V2 receptors in renal collecting ducts → prevents aquaporin-2 insertion → free water excretion without sodium loss ("aquaresis")
• Use in cirrhosis:
  • Contraindicated/use with extreme caution in active hepatitis (high-dose tolvaptan caused elevated transaminases in ADPKD trials)
  • Low-dose tolvaptan may be useful in burned-out cirrhosis (no ongoing liver damage) with:
    • Hyponatremia
    • Fluid overload/refractory ascites
  • Studies show it reduces the need for albumin infusion and degree of ascites accumulation in decompensated cirrhosis
• Other vaptans:

---

PART 2 - BILIARY MANAGEMENT: BILE ACID AGENTS

A. Ursodiol (Ursodeoxycholic Acid - UDCA)

Pharmacokinetics

• Orally absorbed
• Conjugated in the liver with glycine or taurine
• Excreted in bile
• Extensive enterohepatic recirculation
• Serum half-life: ~100 hours
• With long-term daily use: constitutes 30-50% of the circulating bile acid pool
• A small fraction passes into the colon → dehydroxylated by colonic bacteria to lithocholic acid (potentially hepatotoxic, but minimal at therapeutic doses)

Pharmacodynamics

• Bile cholesterol solubility is determined by the ratio of bile acids : lecithin : cholesterol
• Ursodiol does not primarily act by expanding the bile acid pool
• Primary mechanisms:
  1. Reduces hepatic cholesterol secretion → decreases cholesterol content of bile → promotes cholesterol crystal dissolution
  2. Stabilizes hepatocyte canalicular membranes (possibly by reducing toxic endogenous bile acid concentrations)
  3. Anti-inflammatory effects - inhibits immune-mediated hepatocyte destruction
  4. Reduces concentrations of more toxic endogenous bile acids (e.g., chenodeoxycholic, lithocholic acid) through competitive displacement

Clinical Uses

Adverse Effects

• Practically free of serious adverse effects
• Bile salt-induced diarrhea: uncommon
• No hepatotoxicity (unlike chenodeoxycholic acid, its predecessor)

---

B. Obeticholic Acid (Ocaliva)

Mechanism

• Synthetic derivative of chenodeoxycholic acid
• Reduces hepatic concentrations of more toxic endogenous bile acids (same as ursodiol)
• Additionally: ligand for nuclear Farnesoid X Receptor (FXR)
  • FXR modulates: hepatic inflammation, fibrosis, gluconeogenesis, lipid synthesis, insulin sensitivity
  • FXR activation reduces bile acid synthesis (negative feedback via FGF19/CYP7A1 suppression)
  • Anti-fibrotic effects through suppression of hepatic stellate cell activation

Clinical Uses

Adverse Effects

• Pruritus (severe) in up to 25% of patients, especially at 10 mg dose
• Leads to drug discontinuation in ~10% of patients
• Hepatic decompensation risk: use with care in advanced cirrhosis (Child-Pugh B/C)

Other FXR Agonists / Bile Acid Pathway Drugs

---

PART 3 - VARICEAL HEMORRHAGE (Portal Hypertension Complication)

Pathophysiology

• Increased portal blood flow - from low arteriolar resistance due to increased circulating vasodilators (NO, glucagon) + decreased vascular sensitivity to vasoconstrictors
• Increased intrahepatic vascular resistance - fixed fibrosis in spaces of Disse + reversible sinusoidal vasoconstriction

---

A. Somatostatin & Octreotide (ACUTE HEMORRHAGE - First-line)

Octreotide

• Class: Synthetic somatostatin analog
• Mechanism in portal hypertension:
  • Reduces portal blood flow and variceal pressures
  • Does NOT directly contract vascular smooth muscle
  • Mechanism likely: inhibition of release of glucagon and other gut peptides that increase mesenteric blood flow
  • Inhibits release of vasodilatory gut peptides via binding to somatostatin receptors (SSTR2 and SSTR5)
• Use: Active variceal hemorrhage - IV infusion for 3-5 days
  • Dose: 50 mcg/h IV continuous infusion (somatostatin: 250 mcg/h)
  • Promotes initial hemostasis from bleeding esophageal varices (clinical trial data conflicting but generally effective)
• Other somatostatin analogs:

---

B. Vasopressin & Terlipressin

Vasopressin (ADH)

• Class: Polypeptide V1/V2 receptor agonist
• Mechanism: Potent arterial vasoconstrictor → splanchnic arterial vasoconstriction → reduced splanchnic perfusion → lowered portal venous pressures
• Historical use: Previously common for acute variceal hemorrhage
• Current status: No longer used for variceal hemorrhage due to high adverse-effect profile
• Alternative current use: Intra-arterial infusion (via angiography catheter) for GI bleeding from small bowel/large bowel vascular ectasias or diverticulosis
• Adverse effects:
  • Systemic/peripheral vasoconstriction → hypertension, myocardial ischemia/infarction, mesenteric infarction
  • Antidiuretic effects → free water retention → hyponatremia, pulmonary edema
  • Nausea, abdominal cramps, diarrhea
  • Note: Co-administration with nitroglycerin reduces coronary/peripheral vasospasm AND further reduces portal pressure (by reducing portohepatic vascular resistance)

Terlipressin

• Class: Vasopressin analog (V1 receptor agonist prodrug)
• Mechanism: Converted to lysine vasopressin in vivo; selective V1a activation → splanchnic vasoconstriction
• Advantages over vasopressin: Similar efficacy with fewer adverse effects (longer duration, more gradual release)
• Uses: Variceal hemorrhage + hepatorenal syndrome (HRS Type 1) - FDA approved in USA in 2022 for HRS
• Status in USA: Not approved for variceal hemorrhage indication in USA

---

C. Non-selective Beta-blockers (PROPHYLAXIS)

Propranolol & Nadolol

• Class: Non-selective beta-1 + beta-2 receptor antagonists
• Mechanism of portal pressure reduction:
  • Beta-1 blockade → decreased cardiac output → decreased portal inflow
  • Beta-2 blockade → splanchnic vasoconstriction (unopposed alpha-adrenergic effect of circulating catecholamines on vascular smooth muscle)
• Why non-selective is better than selective: Selective beta-1 blockers (metoprolol, atenolol) miss the beta-2-mediated splanchnic vasoconstriction component - thus less effective for portal pressure reduction
• Clinical evidence:
  • Primary prophylaxis (no prior bleed): Reduces incidence of first variceal hemorrhage from 25% → 15% in patients with cirrhosis and varices
  • Secondary prophylaxis (after a bleed): Without treatment, 80% likelihood of recurrent hemorrhage within 2 years; non-selective beta-blockers significantly reduce this rate
• Carvedilol: Non-selective beta + alpha-1 blocker; may be superior to propranolol for portal pressure reduction; increasingly used

---

PART 4 - HEPATIC ENCEPHALOPATHY

A. Lactulose

• Class: Synthetic non-absorbable disaccharide (osmotic agent / GI acidifier)
• Mechanism:
  1. Colonic bacteria metabolize lactulose → lactic acid + acetic acid → acidifies colonic contents
  2. Acidic pH traps ammonia (NH3) as ammonium (NH4+) → cannot be absorbed → excreted in stool
  3. Acts as osmotic laxative → speeds transit → reduces ammonia production time
  4. May also alter colonic flora, reducing ammonia-producing bacteria
• Use: First-line treatment and secondary prophylaxis of hepatic encephalopathy
• Dose: 15-45 mL orally 2-4 times daily; titrate to 2-3 soft stools/day
• Adverse effects: Flatulence, cramping, diarrhea (excessive use causes electrolyte disturbances)

B. Rifaximin (Xifaxan)

• Class: Rifamycin antibiotic derivative; minimally absorbed
• Mechanism: Inhibits bacterial RNA polymerase (beta subunit of DNA-dependent RNA polymerase) → bactericidal → reduces ammonia-producing colonic bacteria
• Pharmacokinetics:
  • Systemic absorption: <0.5% orally
  • High fecal concentrations (up to 8000 mcg/g after 3-day course)
  • No CYP450-mediated drug interactions (unlike rifampin/rifabutin) due to minimal absorption
  • Active against gram-positive and gram-negative aerobes and anaerobes
• Dose: 550 mg twice daily (for hepatic encephalopathy)
• Uses: Management of hepatic encephalopathy (reduces recurrence); travelers' diarrhea; IBS-D; adjunct in recurrent C. difficile
• Advantages over neomycin: Non-toxic (minimal systemic absorption vs. neomycin's nephrotoxicity and ototoxicity)

C. Neomycin (Historical/Rarely Used)

• Class: Aminoglycoside antibiotic
• Mechanism: Suppresses coliform (ammonia-producing) flora in the gut → reduces ammonia production
• Dose: 1 g every 6-8 hours orally with reduced protein intake
• Current status: Largely supplanted by lactulose and rifaximin due to toxicity
• Adverse effects: Nephrotoxicity, ototoxicity (auditory > vestibular); risk persists even with oral use due to partial absorption (especially in inflamed/diseased gut)

---

PART 5 - MILK THISTLE (SILYMARIN) - Hepatoprotective Agent

• Active constituent: Silymarin (mixture of flavonolignans: silybin, silydianin, silychristin)
• Proposed mechanisms:
  1. Reduces lipid peroxidation; scavenges free radicals
  2. Enhances glutathione and superoxide dismutase levels → membrane stabilization
  3. Inhibits lipoxygenase → reduces leukotriene formation (anti-inflammatory)
  4. Inhibits NF-kB (activated in alcoholic/NAFLD, viral hepatitis, biliary disease)
  5. Increases RNA polymerase I activity in healthy hepatocytes (not malignant cells) → enhanced protein synthesis and cell regeneration
  6. Reduces collagen accumulation in cirrhosis models
  7. Reduces TGF-beta expression in hepatic stellate cells → anti-fibrotic
  8. Dose-dependent stimulation of bile flow → potentially beneficial in cholestasis
• Clinical evidence: A systematic review of 13 RCTs (915 patients) showed no significant reduction in all-cause mortality, liver histology, or complications. A significant reduction in liver-related mortality was claimed but only from lower-quality trials. Evidence is currently insufficient to warrant routine clinical use.
• Uses studied: Acute/chronic viral hepatitis, alcoholic liver disease, drug/toxin-induced liver injury

---

COMPLETE DRUG CLASS SUMMARY TABLE

---

---

Liver Failure & Biliary Management - Full Detail (Katzung 16e)

---

PART 1: HEPATIC CIRRHOSIS - ASCITES & EDEMA

Pathophysiology (Why These Drugs Are Chosen)

1. Elevated portal hydrostatic pressure - sinusoidal fibrosis, blocked venous outflow
2. Reduced plasma oncotic pressure - hypoalbuminemia (impaired synthesis)
3. Renal sodium retention - from diminished renal perfusion, diminished plasma volume, and critically - primary aldosterone excess (liver fails to metabolize aldosterone)

---

A. Aldosterone Receptor Antagonists - FIRST LINE

Spironolactone

• Class: Non-selective mineralocorticoid receptor (MR) antagonist
• Mechanism: Competes with aldosterone at renal distal tubule and collecting duct receptors → inhibits ENaC insertion → natriuresis without potassium loss
• Why it excels in cirrhosis: Cirrhotic edema is unusually responsive because the root cause is hyperaldosteronism. Loop diuretics fail partly because they can't overcome the high aldosterone state; spironolactone strikes directly at it.
• Adverse effects:
  • Hyperkalemia - major risk in patients with even mild renal insufficiency; Katzung explicitly says: "considerable caution is necessary"
  • Gynecomastia, menstrual irregularities, impotence - due to anti-androgenic and progestogenic effects (it also blocks androgen and progesterone receptors)

Eplerenone

• Class: Selective MR antagonist only
• Mechanism: Same as spironolactone but no anti-androgenic/progestogenic receptor binding
• Advantage: No gynecomastia or hormonal side effects
• Use: Alternative to spironolactone in cirrhosis; similar efficacy for ascites

---

B. Loop Diuretics - SECOND LINE (Adjunct)

Furosemide

• Class: Loop diuretic; inhibits Na+/K+/2Cl- cotransporter (NKCC2) in the thick ascending limb of Henle
• Why resistance occurs in cirrhosis:
  1. Hypoalbuminemia reduces drug delivery to tubular fluid (furosemide is protein-bound; it reaches the tubule via secretion)
  2. High circulating aldosterone counteracts the natriuresis
• Role: Adjunct to spironolactone; standard practice ratio is spironolactone 100 mg : furosemide 40 mg to maintain normokalemia
• Katzung's critical warning - consequences of overly aggressive diuresis in cirrhosis:
  • Intravascular volume depletion → hepatorenal syndrome (acute kidney injury)
  • Hypokalemia + metabolic alkalosis → hepatic encephalopathy (ammonia production increases with alkalosis)
  • This is worse than in heart failure - "even more disastrous"

---

C. Vaptans - Vasopressin V2-Receptor Antagonists (FOR HYPONATREMIA)

Tolvaptan

• Class: Selective V2-receptor antagonist ("aquaretic")
• Mechanism: Blocks V2 receptors in renal collecting ducts → prevents cAMP-mediated aquaporin-2 channel insertion → free water excretion without sodium loss
• Use in cirrhosis (Katzung's nuanced guidance):
  • Contraindicated/extreme caution in active hepatitis - high-dose tolvaptan caused transaminase elevations in an ADPKD trial
  • Potentially useful in burned-out cirrhosis (no ongoing liver damage) with hyponatremia or fluid overload
  • Studies show: reduced need for albumin infusion + decreased ascites accumulation in decompensated cirrhosis
  • Summary: avoid in active liver damage; may benefit end-stage cirrhosis with hyponatremia

---

PART 2: BILIARY MANAGEMENT - BILE ACID AGENTS

A. Ursodiol (Ursodeoxycholic Acid - UDCA)

Pharmacokinetics

Pharmacodynamics

1. Reduces hepatic cholesterol secretion → less cholesterol in bile → stones dissolve/prevented
2. Stabilizes hepatocyte canalicular membranes - by reducing concentration of toxic endogenous bile acids or inhibiting immune-mediated hepatocyte destruction
3. Anti-inflammatory effects on biliary epithelium
4. Replaces toxic hydrophobic bile acids (chenodeoxycholic, deoxycholic acid) with the nontoxic hydrophilic ursodiol

Clinical Uses

Adverse Effects

• Practically free of serious adverse effects
• Bile salt-induced diarrhea: uncommon
• No hepatotoxicity - unlike chenodeoxycholic acid, its historical predecessor (which caused hepatotoxicity and diarrhea, leading to its abandonment)

---

B. Obeticholic Acid (Ocaliva) - FXR Agonist

Mechanism (Two-Pronged)

1. Bile acid replacement - reduces hepatic concentrations of more toxic endogenous bile acids (same principle as ursodiol)
2. FXR nuclear receptor activation - obeticholic acid is a potent FXR ligand. FXR is a nuclear receptor expressed in liver, intestine, kidney, and adrenals. FXR activation:
   • Reduces bile acid synthesis (via FGF19 signaling → suppresses CYP7A1 and CYP8B1)
   • Reduces hepatic inflammation
   • Reduces fibrosis (suppresses hepatic stellate cell activation)
   • Modulates gluconeogenesis, lipid synthesis, and insulin sensitivity

Clinical Uses

Adverse Effects

• Pruritus (severe) in up to 25% of patients, especially at 10 mg
• Discontinuation due to pruritus: ~10% of patients
• Risk of hepatic decompensation if used in advanced cirrhosis (Child-Pugh B/C patients) - use with reduced dosing frequency

---

PART 3: VARICEAL HEMORRHAGE - PORTAL HYPERTENSION DRUGS

Pathophysiology

• Portal hypertension = increased portal blood flow (from splanchnic vasodilation due to excess NO, glucagon) + increased intrahepatic resistance (fibrosis + reversible sinusoidal vasoconstriction)
• Leads to portosystemic collaterals - esophageal/gastric varices → rupture → massive GI hemorrhage

---

A. Somatostatin & Octreotide

Octreotide

• Class: Synthetic somatostatin analog (8 amino acid cyclic peptide)
• Mechanism in portal hypertension:
  • Reduces portal blood flow and variceal pressures
  • Does not directly contract vascular smooth muscle
  • Mechanism likely: inhibition of glucagon and other vasoactive gut peptides that increase mesenteric blood flow
  • Binds SSTR2 and SSTR5 receptors → inhibits cAMP generation → reduced peptide release
• Dose: 50 mcg/h IV continuous infusion for 3-5 days
• Efficacy: Probably effective for initial hemostasis from bleeding esophageal varices (clinical trial data conflicting, but generally used as standard of care alongside endoscopic therapy)
• Clinical note: Used in combination with endoscopic band ligation or sclerotherapy - the drug is not curative alone

---

B. Vasopressin & Terlipressin

Vasopressin

• Class: Endogenous polypeptide; V1a + V2 receptor agonist
• Mechanism: V1a activation → potent splanchnic arterial vasoconstriction → reduced splanchnic perfusion → lower portal venous pressure
• Current status for varices: NO longer used for variceal hemorrhage - replaced by octreotide
• Current role: Intra-arterial infusion via angiographically placed catheter for bleeding from small/large bowel vascular ectasias or diverticulosis
• Adverse effects (reason for abandonment in variceal bleeding):
  • Hypertension, myocardial ischemia, myocardial infarction, mesenteric infarction (systemic vasoconstriction)
  • Hyponatremia, fluid overload, pulmonary edema (V2-mediated antidiuresis)
  • Nausea, cramps, diarrhea
  • Mitigation: Co-administer nitroglycerin to reduce coronary/peripheral vasospasm AND further reduce portal pressure (by lowering portohepatic vascular resistance)

Terlipressin

• Class: Synthetic vasopressin analog (V1a agonist prodrug - triglycyl-lysine vasopressin)
• Mechanism: Slowly converted to active lysine vasopressin in vivo → selective V1a splanchnic vasoconstriction; more gradual release = fewer cardiovascular spikes
• Uses:
  • Variceal hemorrhage (outside USA)
  • Hepatorenal Syndrome Type 1 (HRS-1) - FDA approved in USA in 2022 for HRS
• Advantages over vasopressin: Similar efficacy, significantly fewer cardiovascular adverse effects

---

C. Non-selective Beta-blockers - PROPHYLAXIS

Propranolol & Nadolol

• Class: Non-selective beta-1 + beta-2 antagonists
• Mechanism of portal pressure reduction:
  1. Beta-1 blockade → reduced cardiac output → reduced portal blood flow
  2. Beta-2 blockade → splanchnic vasoconstriction (unopposed alpha-adrenergic tone from circulating catecholamines acts on mesenteric vessels)
• Why selective beta-1 blockers (metoprolol, atenolol) are less effective: They miss the beta-2-mediated splanchnic vasoconstriction - so they reduce cardiac output but don't constrict the mesenteric vessels
• Clinical evidence:
  • Primary prophylaxis: In patients with cirrhosis + esophageal varices (never bled), reduces hemorrhage risk from 25% → 15%
  • Secondary prophylaxis: After a first bleed, recurrence rate without treatment = 80% within 2 years. Non-selective beta-blockers significantly reduce recurrent hemorrhage (reduction in mortality is less clear)
• Nadolol vs propranolol: Nadolol has longer half-life; once-daily dosing; similar efficacy

---

PART 4: HEPATIC ENCEPHALOPATHY

A. Lactulose - FIRST LINE

• Class: Synthetic non-absorbable disaccharide (galactose + fructose)
• Mechanism - multi-step:
  1. Not absorbed in the small intestine; reaches the colon intact
  2. Colonic bacteria ferment lactulose → lactic acid + acetic acid → colonic acidification (pH drops from ~7 to ~5)
  3. At acidic pH, NH3 (lipid-soluble, absorbable) is converted to NH4+ (ionized, non-absorbable) → ammonia trapped in stool
  4. Osmotic laxative effect → accelerated intestinal transit → less time for ammonia production and absorption
  5. May alter colonic flora composition (reduces ammonia-generating bacteria)
• Dose: 15-45 mL orally 2-4 times daily; titrate to 2-3 soft stools/day; rectal enema for obtunded patients
• Adverse effects: Flatulence, cramping, diarrhea; excessive use → dehydration, electrolyte disturbances

---

B. Rifaximin - FIRST LINE (Combination/Second Line)

• Class: Rifamycin derivative; poorly absorbed GI antibiotic
• Mechanism: Inhibits the beta subunit of bacterial DNA-dependent RNA polymerase → bactericidal against ammonia-producing gut bacteria (gram-positive + gram-negative aerobes and anaerobes)
• Why it works without systemic toxicity:
  • Systemic absorption: <0.5% orally
  • Fecal concentrations: up to 8000 mcg/g (high enough to kill gut bacteria)
  • NO CYP450-mediated drug interactions (unlike rifampin/rifabutin) due to negligible systemic levels
• Dose: 550 mg orally twice daily for hepatic encephalopathy
• Additional uses: Travelers' diarrhea (300 mg TID × 3 days); IBS-D; adjunct in recurrent C. difficile
• Comparison to neomycin: Vastly safer - no nephrotoxicity, no ototoxicity

---

C. Neomycin - Historical/Rarely Used

• Class: Aminoglycoside antibiotic
• Mechanism: Suppresses coliform (ammonia-producing) flora → reduces gut ammonia production
• Dose: 1 g every 6-8 hours orally, with reduced protein intake
• Status: Largely supplanted by lactulose and rifaximin
• Why abandoned: Nephrotoxicity + ototoxicity (auditory > vestibular); even oral neomycin is partially absorbed in patients with inflamed/diseased gut mucosa. Deafness may occur, especially with impaired renal function.

---

PART 5: HEPATOPROTECTIVE AGENT - SILYMARIN (Milk Thistle)

• Source: Silybum marianum (milk thistle)
• Active components: Silymarin (mixture: silybin A/B, silydianin, silychristin)
• Proposed mechanisms:
  1. Antioxidant: reduces lipid peroxidation, scavenges free radicals, enhances glutathione and superoxide dismutase
  2. Membrane stabilization → reduces toxin entry into hepatocytes
  3. Anti-inflammatory: inhibits lipoxygenase → reduces leukothriene formation; inhibits leukocyte migration; inhibits NF-kB (a key inflammatory mediator activated in NAFLD, alcoholic hepatitis, viral hepatitis, biliary disease)
  4. Antifibrotic: reduces collagen accumulation; reduces TGF-beta in hepatic stellate cells
  5. Increases RNA polymerase I activity in healthy hepatocytes (not malignant) → potential for hepatocyte regeneration
  6. Dose-dependent bile flow stimulation → potentially beneficial in cholestasis
• Clinical evidence: Systematic review of 13 RCTs (915 patients) found no significant reductions in all-cause mortality, liver histology, or complications. Insufficient evidence to recommend for clinical use.
• Studied in: Viral hepatitis (B, C), alcoholic liver disease, drug/toxin-induced liver injury

---

COMPLETE REFERENCE TABLE